CAMBRIDGE, Mass. - BostonChron -- In response to the recent emergency medical evacuation from the International Space Station (ISS), Diopter Labs today released mission-readiness data for Bioshare, a dissolvable ocular therapy designed to provide regenerative care in zero-gravity and high-radiation environments.

The Crew-11 evacuation—the first such emergency in the station's 25-year history—has exposed a critical vulnerability: the lack of autonomous, shelf-stable regenerative tools for ocular injuries. Bioshare addresses this by combining the biological power of human amnion with a structural collagen matrix in a self-dissolving lens.

More on Boston Chron

• TravelSMG Announces 2026 European Travel Agent Forum & Confirms 2026 Event Suite
• $500,000 In Grants Awarded to 39 Community Organizations Supporting Black Men and Boys Across Boston Neighborhoods
• Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
• Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
• RAIN Group Wins Three Gold Stevie® Awards

The Regenerative Synergy of Amnion and Collagen

Unlike standard synthetic "bandage" lenses, Bioshare utilizes the natural healing properties of its core components to rebuild damaged ocular tissue:

• Human Amnion: Naturally rich in growth factors (EGF, TGF-beta) and anti-inflammatory cytokines, the amnion layer suppresses scarring and "resets" the healing process in chronic or acute wounds. It acts as a biological substrate, facilitating the rapid migration of epithelial cells to close corneal defects.
• Collagen Matrix: The integrated collagen serves as a 3D structural scaffold. In microgravity, where cellular growth is often delayed, this scaffold provides the necessary architecture for new tissue to take hold, mimicking the eye's native extracellular matrix.

"In a remote environment like the ISS or a future Mars mission, you cannot wait for a surgeon or a refrigerated delivery of biologics," said Chris Adams, CEO at Diopter Labs. "Bioshare is stable at room temperature and leverages the body's own regenerative pathways. By providing both the 'blueprints' (Amnion) and the 'scaffolding' (Collagen), we can stabilize and heal sight-threatening injuries autonomously."

More on Boston Chron

• Planning Department Launches First Boston Planning Academy For Residents
• FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
• $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
• Another 1940's Mystery Novel Set in Gloucester and the Surrounding Areas
• CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety

Built for the "Space Medicine" Kit

Bioshare is engineered to be applied like a standard contact lens, requiring no specialized training or surgical equipment. Its ability to remain stable without refrigeration makes it a vital candidate for the limited-resource medical bays of the next generation of spacecraft.

About Diopter Labs

Diopter Labs (http://diopterlabs.com) is a biotechnology leader in ocular regenerative medicine, focusing on the development of "clinic-in-a-lens" technologies that bridge the gap between emergency trauma and long-term healing.